A study to see how a single increasing dose of the oral drug AD-700 affects the ability of a CT scan to detect activated brown fat in healthy people
This early-stage (Phase 1) clinical trial looks at how a new medicine taken by mouth, called AD-700, affects brown fat in healthy adult men. Unlike normal white fat which stores calories, brown fat burns calories to produce heat. Scientists believe activating brown fat could one day help treat metabolic conditions such as obesity and type 2 diabetes. In this study, healthy male volunteers will take a single dose of AD-700. Researchers will then use specialised CT scans (detailed X-ray images) to check whether the drug switches on brown fat and makes it visible. Because this is a dose-escalation trial, different small groups of volunteers will receive gradually higher doses so researchers can carefully monitor safety. The study will not directly improve your health, but it provides crucial information to help develop future treatments for metabolic disorders.
At a glance
What is this study about?
Most of the fat in our bodies is 'white fat', which stores extra energy from the food we eat. However, humans also have small amounts of 'brown fat'. Brown fat works differently: when activated, it burns sugar and fat to produce body heat. Because of this, scientists are very interested in finding safe ways to turn on brown fat to help tackle metabolic conditions, such as weight issues and diabetes.
This study is testing a new oral medicine known as AD-700. Researchers want to find out whether taking a single dose of AD-700 can switch on brown fat in healthy volunteers. To measure this, doctors will take CT scans, which are detailed, 3D X-ray pictures of the inside of the body. They want to know if the activated fat can be clearly detected on these scans.
This is a Phase 1 study, which is the earliest stage of testing a medicine in people. The main purpose is to check how the drug behaves in the human body, whether it works as expected on brown fat, and what dose is safe and well tolerated. Small groups of volunteers will test increasing doses under close medical supervision.
Taking part in this research helps scientists better understand human metabolism. It could also lead to new imaging techniques that make it easier to test future metabolism medicines.
Key takeaways
- Tests whether a new drug, AD-700, can turn on energy-burning brown fat in humans.
- Uses CT scans to check if activated brown fat can be clearly photographed and measured.
- Open to healthy male volunteers aged 18 and older.
- Involves a single dose of the study medicine under close medical observation.
- Designed to help scientists create future treatments for metabolic disorders.
Who may be eligible?
This trial is specifically looking for healthy adult men aged 18 and older. Because this is a very early safety and imaging study, researchers need volunteers who do not have major underlying health problems, so they can see the drug's clear effects without interference from other conditions.
Only men are being recruited for this particular phase of testing. This is common in early Phase 1 pharmacology trials to reduce biological variables before expanding the research to a wider group of people.
You will likely not be able to join if you have significant ongoing medical issues, such as heart disease, kidney or liver problems, or if you take regular prescription medicines that could interact with AD-700. The study team will run health checks before you can take part to make sure it is completely safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am a man aged 18 or over.
- I consider myself to be in good general health.
- I do not have long-term heart, kidney, or liver conditions.
- I am willing to undergo routine health checks, blood tests, and a CT scan.
- I am available to visit a clinical trial unit for monitoring.
What does participation involve?
If you take part, you will first attend a screening visit at a specialist clinical research unit. The medical team will check your overall health using routine tests, which usually include blood tests, a urine test, a physical examination, and an electrocardiogram (ECG) to monitor your heart rhythm.
If you are eligible, you will be scheduled for the study visit. You will take a single dose of AD-700 by mouth as a tablet or liquid. Afterwards, you will have one or more CT scans so doctors can take pictures of your brown fat. The team will monitor your blood pressure, temperature, heart rate, and collect blood samples to track how your body processes the drug.
You may need to stay at the clinic for part of the day or overnight so the team can monitor you closely. There will also be a follow-up check a few days or weeks later to ensure you feel well. The total time commitment is usually across a few weeks.
Potential risks and benefits
Locations (1)
- —UnverifiedFinland
Common questions
What is brown fat?
Brown fat is a healthy type of body fat that burns calories to create heat when you are cold, unlike white fat which stores extra calories.
Why is this trial only open to men?
Early Phase 1 trials often start with a single sex to keep biological factors as consistent as possible before testing in broader populations.
Will I get paid for taking part?
Phase 1 trials involving healthy volunteers usually offer financial compensation for your time, travel, and inconvenience. The study team can give you exact details.
Is a CT scan painful?
No. A CT scan is completely painless. You will simply need to lie still on a flat bed while the scanner takes pictures around you.
Can I leave the study if I change my mind?
Yes. Taking part is completely voluntary. You have the right to withdraw at any stage, and you do not need to give an explanation.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.